. 2017 Feb 3;7:41624. doi: 10.1038/srep41624

Table 9. Recent reports concerning the use of preoperative TACE on HCCs patients who accepted RFA.

First author	Country	Published Year	Recruitment year	Patient number	Inclusion criteria	Treatment protocol	Patient number	Major complication rate	Response rate (complete/partial)	1-, 3-, and 5-year overall survival rates (%)			P value
Kim¹⁴	Korea	2012	2001–2008	314	2–3 cm	RFA	231	0.4%	99%	93%	73%	53%	P = 0.545
						TACE + RFA	83	1.2%	99%	93%	72%	63%
Kim⁷	Korea	2011	2000–2010	123	3.1–5.0 cm	RFA	66	3%	94%	—	—	23%	P < 0.05
						TACE + RFA	57	0%	98%	—	—	49%
Morimoto²²	Japan	2010	2005–2009	42	3.1–5.0 cm	RFA	18	27.8%	100%	89%	80%	—	P = 0.369
						TACE + RFA	19	5.3%	100%	100%	93%	—
Kim²³	Korea	2013	2008–2010	84	2–5 cm	RFA	47	14.9%	100%	95.7%	84.3%	—	P = 0.631
						TACE + RFA	37	2.7%	100%	97.3%	78.4%	—
Cheng⁵³	China	2008	2001–2004	196	Larger than 3 cm	RFA	100	5%	37%/32%	67%	32%	8%	P < 0.01
						TACE + RFA	96	10.4%	55%/24%	83%	55%	31%
Peng¹⁰	China	2012	2002–2006	139	Less than 5 cm	RFA	70	2.8%	100%	82%	47%	36%	P = 0.037
						TACE + RFA	69	2.9%	100%	94%	69%	46%
Yang⁵⁴	China	2009	2000–2007	103	Recurrence after resection	RFA	37	2.7%	100%	73.9%	51.1%	28.0%	P < 0.05
						TACE + RFA	31	3.2%	100%	88.5%	64.6%	44.3%
Shibata²⁴	Japan	2009	2003–2007	89	≤3 cm	RFA	43	2%	100%	100%	84.5%	74%	P = 0.515
						TACE + RFA	46	2%	100%	100%	84.8%	72.7%
Yang⁵⁵	China	2008	2004–2006	78	No limit	RFA	12	—	47.8%	57.6%	52.3%	—	P < 0.01
						TACE + RFA	31	—	88.6%	81.20%	77.1%	—
Present study	China	present	2005–2009	244	BCLC 0-A/B	RFA	81	3.1%	100%	91.4%	79.10%	60.7%	0.958
						TACE + RFA	163	4.9%	100%	91.4%	77.8%	61.7%

BCLC: Barcelona Clinic Liver Cancer; TACE: transarterial chemoembolization; RFA: Radiofrequency ablation; LT: liver transplantation.